臨床醫(yī)學(xué)文獻檢索閱讀評價與應(yīng)用

臨床醫(yī)學(xué)文獻檢索、閱讀、評價與應(yīng)用

檢索途徑Medline檢索保存和跟蹤檢索結(jié)果獲取全文的途徑其他途徑Google題目英文關(guān)鍵詞filetype:PDF聯(lián)系作者論壇代理重要工具閱讀的目的了解臨床證據(jù)---CochraneLibrary，ClinicalEvidence，高IFSCI論文最新進展—Pubmed-Abstract研究方法—Methods講演、興趣—-精讀了解背景---Introduction相互比較---Discussion評價質(zhì)量---Methods文章的結(jié)構(gòu)TitleandrunningtitleAuthorsandaddressesAbstractKeywordsandabbreviationsIntroductionMaterialsandmethodsResultsDiscussionAcknowledgmentsReferencesTablesandfigures

TitleAbstractFiguresTablesResultsanddiscussionRestofthepaper(J.K.Ladha)影響因子〔ImpactFactor〕發(fā)表文章篇數(shù)：2021=597，2021=577；合計=11742021年引用次數(shù)：2021=4341，2021=4122；合計=8463IF=8463/1174=7.2092021年6月中下旬公布文章質(zhì)量評價Jadad評分CochraneHandbookCochraneBackReviewGroupCONSORT聲明Jadad評分隨機分組序列的產(chǎn)生方法2分：計算機或隨機數(shù)字表1分：提到隨機，但未詳細(xì)說明0分：半隨機或未隨機雙盲2分：描述了實施雙盲的具體方法并且被認(rèn)為是恰當(dāng)?shù)?，如采用完全一致的撫慰劑?分：試驗僅提及采用雙盲法0分：試驗提及采用雙盲，但方法不恰當(dāng)，如比較片劑與注射劑而未提及使用雙偽法退出與失訪1分：詳細(xì)說明了退出與失訪的理由0分：沒有提及CochraneBack

ReviewGroupFurlanAD,PennickV,BombardierC,vanTulderM,theEditorialBoardoftheCochraneBackReviewGroup.2021UpdatedmethodguidelinesforsystematicreviewsintheCochraneBackReviewGroup.Spine2021;34(18):1929–41.CONSORT清單詳細(xì)內(nèi)容引言BroadinformationontopicPreviousresearchNarrowerbackgroundinformationNeedforstudyFocusofpaperHypothesisandPurposeSurgeryisthetreatmentofchoiceforpatientswithdiseasestageIandIInon-smallcelllungcancer(NSCLC)…AnNSCLCmeta-analysiscombinedtheresultsfromeightrandomisedtrialsofsurgeryversussurgeryplusadjuvantcisplatin-basedchemotherapyandshowedasmall,butnotsignificant(p=0.08),absolutesurvivalbenefitofaround5%at5years(from50%to55%).Atthetimethecurrenttrialwasdesigned(mid-1990s),adjuvantchemotherapyhadnotbecomestandardclinicalpractice…Theclinicalrationaleforneo-adjuvantchemotherapyisthree-fold:regressionoftheprimarycancercouldbeachievedtherebyfacilitatingandsimplifyingorreducingsubsequentsurgery;undetectedmicro-metastasescouldbedealtwithatthestartoftreatment;andtheremightbeinhibitionoftheputativestimulustoresidualcancerbygrowthfactorsreleasedbysurgeryandbysubsequentwoundhealing…Thecurrenttrialwasthereforesetuptocompare,inpatientswithresectableNSCLC,surgeryaloneversusthreecyclesofplatinum-basedchemotherapyfollowedbysurgeryintermsofoverallsurvival,qualityoflife,pathologicalstaging,resectabilityrates,extentofsurgery,andtimetoandsiteofrelapse.CONSORT清單詳細(xì)內(nèi)容CONSORT清單詳細(xì)內(nèi)容〔續(xù)一〕CONSORT清單詳細(xì)內(nèi)容〔續(xù)二〕CONSORT清單詳細(xì)內(nèi)容〔End〕CONSORTGroup.CONSORT2021Statement:UpdatedGuidelinesforReportingParallelGroupRandomizedTrials.AnnInternMed.2021;152.DavidMoher,etal.CONSORT2021ExplanationandElaboration:updatedguidelinesforreportingparallelgrouprandomisedtrials.BMJ2021;340:c869評價對象例數(shù)n=排除例數(shù)n=例，不符合例，拒絕參與例，其它原因例。隨機分組例數(shù)n=分配至實驗組例數(shù)n=接受分配例,不接受分配例…分配至對照組例數(shù)n=接受分配例,不接受分配例…失訪例數(shù)n=未依從計劃例失訪例數(shù)n=未依從計劃例納入分析例數(shù)n=排除分析例數(shù)n=納入分析例數(shù)n=排除分析例數(shù)n=CONSORT流程圖好文章的要求〔4C〕Clear：思路清晰、邏輯性強、概念清楚、層次清楚、表達清楚、語句通順Complete：內(nèi)容完整、結(jié)構(gòu)完整，忌虎頭蛇尾Correct：內(nèi)容正確，數(shù)據(jù)數(shù)據(jù)正確、可信，文法